Drugs / PYEX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06666010 | Jan 2025 → Jan 2028 expected | substance-related disorder | Filament Health Corp. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PYEX | “The investigational medicinal product PEX010, containing 25 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.” NCT06666010 ↗ |
| Route | Oral | “capsule for oral administration” NCT06666010 ↗ |